Inhibikase Therapeutics, Inc.
IKT
$1.67
-$0.01-0.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -16.38M | -12.73M | -11.93M | -9.92M | -13.68M |
| Total Depreciation and Amortization | -- | 0.00 | 23.70K | 24.20K | 12.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.37M | 4.81M | 3.46M | 3.85M | 8.23M |
| Change in Net Operating Assets | -50.40K | 409.20K | -2.15M | 466.80K | 1.33M |
| Cash from Operations | -12.06M | -7.52M | -10.59M | -5.57M | -4.10M |
| Capital Expenditure | -- | 0.00 | 0.00 | 0.00 | -13.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -80.48M | -98.80K | -28.75M | 9.84M | 21.07M |
| Cash from Investing | -80.48M | -98.80K | -28.75M | 9.84M | 21.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.90M | 108.18M | 250.90K | 31.80K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 385.10K | -385.10K | -- | -- |
| Cash from Financing | 2.90M | 108.57M | -134.10K | 31.80K | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.65M | 100.95M | -39.47M | 4.30M | 16.95M |